REZANT Trademark

Trademark Overview


On Tuesday, February 26, 2013, a trademark application was filed for REZANT with the United States Patent and Trademark Office. The USPTO has given the REZANT trademark a serial number of 85860214. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, October 10, 2016. This trademark is owned by Novartis AG. The REZANT trademark is filed in the Pharmaceutical Products category with the following description:

(Based on Intent to Use) Anti-infectives; Anti-inflammatories; Antibacterial pharmaceuticals; Antibiotics; Antifungal preparations; Antivirals; Cardiovascular pharmaceuticals; Dermatological pharmaceutical products; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system, the metabolic system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pha...
rezant

General Information


Serial Number85860214
Word MarkREZANT
Filing DateTuesday, February 26, 2013
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, October 10, 2016
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 9, 2013

Trademark Statements


Goods and Services(Based on Intent to Use) Anti-infectives; Anti-inflammatories; Antibacterial pharmaceuticals; Antibiotics; Antifungal preparations; Antivirals; Cardiovascular pharmaceuticals; Dermatological pharmaceutical products; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system, the metabolic system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; (Based on 44(e)) Anti-infectives; Anti-inflammatories; Antibacterial pharmaceuticals; Antibiotics; Antifungal preparations; Antivirals; Cardiovascular pharmaceuticals; Dermatological pharmaceutical products; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system, the metabolic system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, March 4, 2013
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameNovartis AG
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBasel
CH

Party NameNovartis AG
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBasel
CH

Trademark Events


Event DateEvent Description
Tuesday, October 11, 2016ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, October 10, 2016ABANDONMENT - NO USE STATEMENT FILED
Wednesday, March 9, 2016NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 8, 2016EXTENSION 5 GRANTED
Tuesday, March 1, 2016EXTENSION 5 FILED
Tuesday, March 1, 2016TEAS EXTENSION RECEIVED
Friday, September 4, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 3, 2015EXTENSION 4 GRANTED
Monday, August 31, 2015EXTENSION 4 FILED
Monday, August 31, 2015TEAS EXTENSION RECEIVED
Friday, March 6, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 5, 2015EXTENSION 3 GRANTED
Friday, February 27, 2015EXTENSION 3 FILED
Friday, February 27, 2015TEAS EXTENSION RECEIVED
Tuesday, September 16, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 15, 2014EXTENSION 2 GRANTED
Monday, September 1, 2014EXTENSION 2 FILED
Monday, September 15, 2014CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, September 1, 2014TEAS EXTENSION RECEIVED
Tuesday, March 4, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, February 28, 2014EXTENSION 1 GRANTED
Friday, February 28, 2014EXTENSION 1 FILED
Friday, February 28, 2014TEAS EXTENSION RECEIVED
Tuesday, September 3, 2013NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 9, 2013OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 9, 2013PUBLISHED FOR OPPOSITION
Wednesday, June 19, 2013NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 4, 2013APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, June 3, 2013ASSIGNED TO EXAMINER
Monday, March 4, 2013NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, March 1, 2013NEW APPLICATION ENTERED IN TRAM